Breast cancer survivors (BCSs) who initiate adjuvant therapy with nonsteroidal aromatase inhibitors (NSAIs) experience various genitourinary signs and symptoms associated with menopausal stage. This evidence concerns the gene CYP19A1 and breast carcinoma.